Johnson & Johnson: positive results for colitis drug
(CercleFinance.com) - Johnson & Johnson's Janssen today announced new data from a Phase 3 study showing that a significantly greater proportion of adult patients with moderate-to-severe ulcerative colitis receiving Stelara subcutaneous maintenance therapy were in clinical remission at one year, compared to patients receiving placebo.
Results demonstrated that 44% of adult patients with moderate to severe ulcerative colitis receiving Stelara injections every 8 weeks and 38% receiving injections every 12 weeks achieved clinical remission at week 44, compared to 24% of patients who received placebo.
These data were presented as part of the Congress of the European Crohn's and Colitis Organisation (ECCO) in Copenhagen.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Results demonstrated that 44% of adult patients with moderate to severe ulcerative colitis receiving Stelara injections every 8 weeks and 38% receiving injections every 12 weeks achieved clinical remission at week 44, compared to 24% of patients who received placebo.
These data were presented as part of the Congress of the European Crohn's and Colitis Organisation (ECCO) in Copenhagen.
Copyright (c) 2019 CercleFinance.com. All rights reserved.